Armistice Capital’s Alto Neuroscience ANRO Stock Holding History

Armistice Capital’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.8M	Sell	864,000 -48,000	-5%	-$1.11M	0.28%	57
2026 Q1	$20.5M	Sell	912,000 -624,000	-41%	-$11.6M	0.36%	57
2025 Q4	$27.3M	Sell	1,536,000 -100,000	-6%	-$1.26M	0.33%	48
2025 Q3	$6.58M	Buy	1,636,000 +12,000	+0.7%	+$39.8K	0.1%	100
2025 Q2	$3.57M	Buy	1,624,000 +24,000	+2%	+$57.1K	0.06%	111
2025 Q1	$3.46M	Buy	1,600,000 +950,000	+146%	+$3.4M	0.05%	130
2024 Q4	$2.75M	Buy	+650,000	New	+$4.06M	0.04%	138

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Armistice Capital's ANRO Position: Q2 2026 in Review

Armistice Capital reduced its Alto Neuroscience (ANRO) stake by 5.3% in Q2 2026, selling an estimated $1.11M and leaving 864,000 shares worth $22.8M. The position accounts for 0.28% of the portfolio, ranked #57.

Armistice Capital first reported a position in ANRO in Q4 2024 and has held it in 7 quarters since. The position peaked at $27.3M in Q4 2025. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

Armistice Capital held 864,000 shares of Alto Neuroscience worth $22.8M as of Q2 2026.
Armistice Capital sold 48,000 Alto Neuroscience shares in Q2 2026, an estimated $1.11M.
Alto Neuroscience made up 0.28% of Armistice Capital's portfolio in Q2 2026, its #57 holding.
Armistice Capital first reported a position in Alto Neuroscience in Q4 2024 and has held it in 7 quarters since.
Armistice Capital's Alto Neuroscience position peaked at $27.3M in Q4 2025.
114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.